敲除CAR T细胞中的DNMT3A可防止耗竭并增强抗肿瘤活性
该研究报道人CAR T细胞耗竭是通过表观遗传抑制T细胞多能发育潜能实现的。在表达第一代或第二代CAR的T细胞中敲除从头DNA甲基转移酶3α(DNMT3A),可在长期肿瘤暴露中普遍保持细胞增殖和抗肿瘤应答能力。这种抗耗竭的DNMT3A敲除CAR T细胞功能增强与白细胞介素-10上调相耦合,全基因组DNA甲基化谱定义了表观遗传沉默靶基因图谱。
要点
- 敲除DNMT3A可防止人CAR T细胞耗竭并增强抗肿瘤活性。
- DNMT3A敲除CAR T细胞功能增强与白细胞介素-10上调相耦合。
- 全基因组DNA甲基化谱定义了CAR T细胞耗竭的表观遗传沉默基因图谱。
核心结论
- 人CAR T细胞耗竭通过表观遗传抑制T细胞多能发育潜能实现,敲除DNMT3A可防止耗竭并增强抗肿瘤活性。
研究设计与样本
- 在表达第一代或第二代CAR的人T细胞中敲除DNMT3A,进行功能与全基因组DNA甲基化谱分析。
主要发现
- 敲除DNMT3A的CAR T细胞在长期肿瘤暴露中普遍保持增殖和抗肿瘤应答能力。
- DNMT3A敲除CAR T细胞功能增强与白细胞介素-10上调相耦合。
- 全基因组DNA甲基化谱定义了包括CD28、CCR7、TCF7和LEF1等限制免疫细胞干性的转录调控因子在内的表观遗传沉默基因图谱。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cell therapy is revolutionizing cancer immunotherapy for patients with B cell malignancies and is now being developed for solid tumors and chronic viral infections. Although clinical trials have demonstrated the curative potential of CAR T cell therapy, a substantial and well-established limitation is the heightened contraction and transient persistence of CAR T cells during prolonged antigen exposure. The underlying mechanism(s) for this dysfunctional state, often termed CAR T cell exhaustion, remains poorly defined. Here, we report that exhaustion of human CAR T cells occurs through an epigenetic repression of the T cell’s multipotent developmental potential. Deletion of the de novo DNA methyltransferase 3 alpha (DNMT3A) in T cells expressing first- or second-generation CARs universally preserved the cells’ ability to proliferate and mount an antitumor response during prolonged tumor exposure. The increased functionality of the exhaustion-resistant DNMT3A knockout CAR T cells was coupled to an up-regulation of interleukin-10, and genome-wide DNA methylation profiling defined an atlas of genes targeted for epigenetic silencing. This atlas provides a molecular definition of CAR T cell exhaustion, which includes many transcriptional regulators that limit the “stemness” of immune cells, including CD28, CCR7, TCF7, and LEF1. Last, we demonstrate that this epigenetically regulated multipotency program is firmly coupled to the clinical outcome of prior CAR T cell therapies. These data document the critical role epigenetic mechanisms play in limiting the fate potential of human T cells and provide a road map for leveraging this information for improving CAR T cell efficacy.
引用
- Prinzing B, Zebley CC, Petersen CT, et al. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci Transl Med. 2021. PMID: 34788079. doi:10.1126/scitranslmed.abh0272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。